查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984134

数位生物标记市场：按组件、生物标记类型、功能、治疗领域、应用和最终用户划分——2026年至2032年全球市场预测

Digital Biomarkers Market by Component, Biomarker Type, Functionality, Therapeutic Area, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

数位生物标记市场预计到 2025 年将达到 23.6 亿美元，到 2026 年将成长到 26.1 亿美元，到 2032 年将达到 49.5 亿美元，年复合成长率为 11.16%。

主要市场统计数据
基准年 2025 23.6亿美元
预计年份：2026年 26.1亿美元
预测年份 2032 49.5亿美元
复合年增长率 (%) 11.16%

数位生物标誌物的兴起是推动个人化医疗转型和临床洞察创新的驱动力。

随着数位生物标记重新定义病患监测、诊断和治疗方法方案的製定，医疗保健产业正经历一场根本性的变革。透过先进的感测器、穿戴式装置和植入式装置收集生理和行为数据，这些新的指标使临床医生能够持续而非间断地评估患者的健康状况。从依赖间断检查室测量和影像学检查的传统生物标记到数位生物标记的演变，标誌着疾病检测、追踪和治疗方式的模式转移。

下一波创新浪潮：技术进步与监管突破塑造数位生物标誌物的未来

在技​​术突破、监管进步和患者期望不断变化等因素的推动下，数位生物标记领域正经历着一场变革。感测器小型化和能源效率提升方面的突破，拓展了可在临床环境之外收集的生理讯号范围。穿戴式装置即时采集数据，能够持续监测生命征象、活动模式和睡眠指标，为早期疗育和更具针对性的治疗方案製定创造了机会。

评估 2025 年美国关税政策对数位生物标记开发供应链韧性和零件筹资策略的溢出效应。

美国新关税的实施为数位生物标记设备及其组件的开发人员和製造商带来了挑战和机会。进口感测器、微电子产品和先进材料的关税提高，正在推动筹资策略和供应链结构的变革。为了因应这些变化，企业正在探索替代采购途径，并实现供应商多元化，以缓解成本压力。

从观点分析数位生物标记生态系统，包括其组成部分、功能和治疗重点。

对数位生物标记生态系统的多方面观点检验了六个关键的细分标准，每个标准都对市场动态和技术发展轨迹提供了细緻的见解。对各组成部分的分析表明，该系统存在硬体和软体二分法，其中硬体又可细分为植入式装置、感测器和穿戴式装置。穿戴式装置可进一步细分为健身手环和智慧型手錶。这种区分凸显了感测器外形规格如何影响资料可靠性和使用者接受度；小型植入式装置更适合持续的生理监测，而消费性穿戴装置则优先考虑易用性和使用者参与度。

该计画旨在分析全球数位生物标记市场中不同地区的采用率差异，并专注于监管协调和创新丛集。

区域趋势反映了监管环境、医疗基础设施和投资环境的差异，对数位生物标记的应用和成熟起着至关重要的作用。在北美，创新中心引领潮流，主导科技公司与医疗服务提供者之间强有力的伙伴关係；而在拉丁美洲，试验计画正在探索，旨在将远端监测能力扩展到资源匮乏的地区。该地区对以患者为中心的价值提案的关注，正在加速医保报销方面的对话，并建立新的医疗服务模式。

介绍透过策略合作和技术融合推动数位生物标誌物整合的主要企业。

主要企业正在製定策略路线图，以保持其领先地位，并加速将数位生物标记整合到主流医疗保健中。科技巨头正透过收购专业感测器Start-Ups来扩展其设备产品组合，并透过与数据分析公司合作来增强人工智慧 (AI) 能力。成熟的医疗设备製造商正在将数位终端整合到其现有平台中，以提高临床试验数据的精细度并实现远端病人参与。

透过互通性、病人参与和供应链韧性来维持竞争优势的策略挑战

产业领导企业必须采取多管齐下的方法，才能最大限度地利用数位生物标记带来的机会，并驾驭日益复杂的生态系统。投资于符合新资料交换标准的互通平台，可以简化与电子健康记录和分析工具的集成，从而加快获得洞见的速度。与监管机构合作，优先建立严格的检验框架，可确保数位终点符合临床试验和报销要求，从而促进更广泛的认可。

透过结合一手访谈、文献分析和资料三角验证，我们对数位生物标记有了全面的了解。

本分析整合了严谨的混合方法研究途径所获得的洞见。主要研究包括对50多位相关人员的深入访谈，其中包括医疗设备製造商、软体开发商、医疗服务提供者和监管专家。这些访谈揭示了目前的检验实践、商业化策略以及他们认为的应用障碍。

整合数位生物标记创新和协作框架，为医疗保健转型规划道路。

数位生物标记体现了技术创新与临床需求的融合，为改善患者照护、提高药物研发效率以及变革医疗服务模式开闢了前所未有的机会。连续感测、先进分析和以患者为中心的设计理念的整合，正在重新定义我们监测健康、诊断疾病和优化治疗方法的方式。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 数位生物标记市场：按组件划分

  • 硬体
    • 嵌入式装置
    • 感应器
    • 穿戴式装置
      • 健身手环
      • 智慧型手錶
  • 软体

第九章：按生物标誌类型分類的数位生物标记市场

  • 活动类型
  • 被动的

第十章：数位生物标记市场：功能

  • 连续型
  • 事件驱动
  • 常

第十一章 数位生物标记市场：依治疗领域划分

  • 循环系统
    • 心律不整
    • 心臟衰竭
  • 内分泌学
    • 糖尿病
    • 甲状腺疾病
  • 神经病学
    • 阿兹海默症
    • 帕金森氏症
  • 肿瘤学
    • 乳癌
    • 摄护腺癌
  • 呼吸内科

第十二章 数位生物标记市场：依应用划分

  • 疾病诊断
  • 药物发现
  • 病患监测

第十三章 数位生物标记市场：依最终用户划分

  • 学术和研究机构
  • 生技公司
  • 医院和诊所
  • 製药公司

第十四章 数位生物标记市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：数位生物标记市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 数位生物标记市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国数位生物标记市场

第十八章：中国数位生物标记市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • ActiGraph, LLC
  • Adherium Limited
  • Altoida, Inc.
  • Amgen Inc.
  • Aural Analytics, Inc. by Linus Health, Inc.
  • Biofourmis Pte. Ltd.
  • Biogen Inc.
  • Brainomix Limited
  • Chugai Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Empatica Inc.
  • F. Hoffmann-La Roche Ltd.
  • Feel Therapeutics Inc.
  • GERO PTE. LTD.
  • Huma Therapeutics Limited
  • ICON PLC
  • IXICO PLC
  • Koneksa Health Inc.
  • Medable Inc.
  • Owkin, Inc.
  • Sonde Health, Inc
  • Teva Pharmaceutical Industries Ltd.
  • Verily Life Sciences, LLC
  • VivoSense, Inc
Product Code: MRR-5C6F41F5AF45

The Digital Biomarkers Market was valued at USD 2.36 billion in 2025 and is projected to grow to USD 2.61 billion in 2026, with a CAGR of 11.16%, reaching USD 4.95 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.36 billion
Estimated Year [2026] USD 2.61 billion
Forecast Year [2032] USD 4.95 billion
CAGR (%) 11.16%

Navigating the Emergence of Digital Biomarkers as a Transformational Force in Personalized Healthcare and Clinical Insight Innovation

The healthcare sector is experiencing a fundamental shift as digital biomarkers redefine the landscape of patient monitoring, diagnostics, and therapeutic development. By capturing physiological and behavioral data through sophisticated sensors, wearables, and implantable devices, these novel indicators are enabling clinicians to assess health status continuously rather than episodically. The evolution from traditional biomarkers, which rely on intermittent laboratory measurements or imaging, to digital biomarkers represents a paradigm change in how diseases are detected, tracked, and treated.

In parallel, advancements in data analytics, machine learning algorithms, and cloud computing infrastructures have accelerated the ability to extract meaningful insights from high-volume, high-velocity streams of patient data. As a result, stakeholders across the healthcare continuum-from pharmaceutical companies to hospitals and research institutes-are integrating digital biomarkers into clinical trials, remote monitoring programs, and real-world evidence studies. This introduction presents the foundational concepts and underscores the transformative potential that digital biomarkers hold for enhancing patient outcomes, optimizing care pathways, and driving innovation within a more connected ecosystem.

Unveiling the Next Wave of Innovation: Technological Advances and Regulatory Breakthroughs Shaping the Future of Digital Biomarkers

The landscape of digital biomarkers is undergoing transformative shifts driven by technological breakthroughs, regulatory evolution, and changing patient expectations. Breakthroughs in sensor miniaturization and power efficiency have expanded the range of physiological signals that can be captured outside clinical settings. Real-time data collection from wearable devices now enables continuous monitoring of vital signs, activity patterns, and sleep metrics, creating opportunities for early intervention and more adaptive treatment regimens.

At the same time, regulatory agencies have begun to recognize digital biomarkers as legitimate endpoints in clinical trials, paving the way for faster approvals and broader adoption. Harmonized guidelines are emerging that emphasize data quality, validation protocols, and patient privacy safeguards. This regulatory clarity is empowering software developers and device manufacturers to collaborate more confidently on integrated platforms, ensuring interoperability and compliance across jurisdictions.

Concurrently, patients are increasingly demanding personalized care experiences that reflect their lifestyles and preferences. The convergence of patient-centric design principles with advanced analytics is fostering the development of digital health ecosystems where individuals can actively participate in their treatment journeys. As these transformative elements converge, stakeholders must navigate the complex interplay of innovation, regulation, and user engagement to fully realize the promise of digital biomarkers.

Evaluating the Ripple Effects of 2025 US Tariff Policies on Supply Chain Resilience and Component Sourcing Strategies in Digital Biomarker Development

The implementation of new tariff measures in the United States has introduced challenges and opportunities for developers and manufacturers of digital biomarker devices and components. Imported sensors, microelectronics, and advanced materials now face increased duties, which has led to shifts in sourcing strategies and supply chain configurations. In response, companies are exploring alternate procurement channels and diversifying supplier portfolios to mitigate cost pressures.

These tariff-induced dynamics have accelerated investments in domestic manufacturing capabilities, reducing reliance on cross-border shipments and enhancing supply chain resilience. Emerging partnerships between hardware producers and contract manufacturers are focusing on localizing production hubs, incorporating lean manufacturing techniques, and optimizing component designs to minimize reliance on high-cost imports. In parallel, some stakeholders have begun redesigning device architectures to utilize semiconductors and sensor modules that are exempt from elevated duties, ensuring continued innovation while preserving cost efficiencies.

Ultimately, while the cumulative impact of tariff policy has created short-term adjustments, it has also stimulated a strategic realignment toward more agile, vertically integrated operations. Companies that can adapt swiftly to these evolving trade parameters will be better positioned to deliver next-generation digital biomarker solutions with greater responsiveness to market demands.

Dissecting the Digital Biomarker Ecosystem Through Multifaceted Component, Functionality, and Therapeutic Focus Lenses

In examining the digital biomarker ecosystem through a multidimensional lens, six primary segmentation criteria emerge, each offering nuanced insights into market dynamics and technological trajectories. Component analysis reveals a dichotomy between hardware and software, with hardware further delineated into implantables, sensors, and wearables; the latter grouping subdivides into fitness bands and smartwatches. This distinction underscores how sensor form factors influence data fidelity and user adoption, with smaller implantable devices suited for continuous physiological monitoring and consumer-grade wearables prioritizing ease of use and engagement.

Biomarker types bifurcate into active indicators, which require user engagement or specific stimuli to generate data, and passive indicators that capture signals without direct patient interaction. This differentiation shapes the design of monitoring protocols and informs validation strategies for clinical integration. Functionality segmentation highlights continuous monitoring applications that track health metrics in real time, event-driven models that trigger data capture upon detecting predefined thresholds, and periodic assessments conducted at scheduled intervals. Each modality aligns with different clinical objectives, from chronic disease management to acute event detection.

Applications extend across disease diagnostics, where digital signatures complement traditional tests; drug development programs that employ sensor-derived endpoints to assess therapeutic efficacy; and patient monitoring initiatives that facilitate remote care pathways. End users encompass academic and research institutes pioneering exploratory studies, biotechnology firms driving product innovation, hospitals and clinics integrating digital data into care delivery, and pharmaceutical companies seeking to enrich clinical trials with real-world evidence. Therapeutic areas of focus include cardiology-addressing arrhythmia and heart failure-endocrinology tackling diabetes mellitus and thyroid disorders, neurology with emphasis on Alzheimer's and Parkinson's diseases, oncology concentrating on breast and prostate cancers, and pulmonology monitoring respiratory function. Together, these layers of segmentation reveal the complexity of stakeholder needs and technological opportunities driving digital biomarker advancement.

Mapping Regional Adoption Variances Highlighting Regulatory Harmonization and Innovation Clusters Across Global Digital Biomarker Markets

Regional dynamics play a pivotal role in shaping the adoption and maturation of digital biomarkers, reflecting diverse regulatory frameworks, healthcare infrastructures, and investment landscapes. In the Americas, innovation hubs in North America lead the charge with robust partnerships between technology firms and healthcare providers, while Latin American markets explore pilot programs to extend remote monitoring capabilities across under-resourced areas. This region's emphasis on patient-centric value propositions is accelerating reimbursement dialogues and forging new care delivery models.

Across Europe, the Middle East, and Africa, regulatory convergence initiatives are fostering harmonized data governance standards, enabling cross-border clinical studies and streamlined device approvals. Western European nations are integrating digital biomarkers into national health systems, leveraging public-private collaborations to scale remote care, whereas emerging markets in the region are prioritizing low-cost sensor solutions tailored to local epidemiological profiles. In parallel, nascent digital health consortia in select Middle East and African countries are focusing on capacity building and infrastructure development.

In the Asia-Pacific, rapid digitalization, strong government support for smart healthcare initiatives, and high smartphone penetration rates are driving widespread adoption of wearable-based monitoring. Local manufacturers are optimizing production costs and customizing devices to regional biometrics, while cross-industry alliances are developing ecosystem platforms that integrate hospital networks, insurers, and technology providers. The varied pace of regulatory maturity across the region underscores the need for adaptive market entry strategies.

Profiling Leading Organizations Advancing Digital Biomarker Integration Through Strategic Alliances and Technology Convergence

Key companies are forging strategic pathways to maintain leadership and accelerate the integration of digital biomarkers into mainstream healthcare. Technology giants are expanding their device portfolios through acquisitions of specialized sensor startups and forming alliances with data analytics organizations to bolster artificial intelligence capabilities. Established medical device firms are embedding digital endpoints into legacy platforms, enhancing clinical trial data granularity and enabling remote patient engagement.

Biotechnology innovators are leveraging strategic partnerships with contract research organizations to validate digital endpoints in early-phase studies, while software vendors are investing in cloud-native architectures to ensure scalability and interoperability with electronic health record systems. Collaborative ventures between pharmaceutical companies and sensor manufacturers are focusing on co-development agreements that align therapeutic protocols with adaptive monitoring solutions. Additionally, cross-sector consortia are being established to define industry standards, promote data sharing frameworks, and advance regulatory acceptance of sensor-based outcomes.

Strategic Imperatives for Maintaining Competitive Edge Through Interoperability, Patient Engagement, and Supply Chain Resilience

Industry leaders must adopt a multi-pronged approach to capitalize on digital biomarker opportunities and navigate an increasingly complex ecosystem. Investing in interoperable platforms that adhere to emerging standards for data exchange will streamline integrations with electronic health records and analytical tools, reducing time to insight. Prioritizing rigorous validation frameworks in collaboration with regulatory bodies will ensure that digital endpoints meet clinical trial and reimbursement requirements, fostering broader acceptance.

Cultivating patient-centric design practices, including co-creation workshops with end users, will enhance device usability and long-term engagement. Leaders should also pursue partnerships across the healthcare value chain-from payors to contract research organizations-to co-develop outcome-based models that demonstrate the real-world impact of digital biomarkers. Building resilient supply chains through diversified sourcing and on-shore manufacturing capabilities will mitigate risks associated with trade policy fluctuations.

Finally, establishing robust data governance and privacy safeguards will protect patient trust and align with global regulations. By integrating these strategic imperatives, organizations can drive sustainable growth, deliver enhanced clinical insights, and unlock new value propositions in digital health.

Combining Primary Interviews, Literature Analysis, and Data Triangulation to Derive Comprehensive Digital Biomarker Insights

This analysis synthesizes insights derived from a rigorous mixed-methods research approach. Primary research included in-depth interviews with over 50 stakeholders spanning device manufacturers, software developers, healthcare providers, and regulatory experts. These conversations elucidated current validation practices, commercialization strategies, and perceived barriers to adoption.

Secondary research involved a comprehensive review of peer-reviewed journals, technical white papers, and regulatory guidance documents to ensure factual accuracy and contextual relevance. Industry databases and public filings were examined to trace recent partnerships and technology integrations, while case studies provided practical examples of digital biomarker deployment in clinical and real-world settings. All data underwent cross-validation through triangulation techniques to reinforce credibility and mitigate potential biases.

The resulting insights reflect a holistic understanding of technological trends, policy influences, and stakeholder priorities shaping the digital biomarker landscape today.

Synthesizing Digital Biomarker Innovations and Collaborative Frameworks to Chart a Course for Healthcare Transformation

Digital biomarkers represent a convergence of technological innovation and clinical necessity, unlocking unprecedented opportunities to enhance patient care, streamline drug development, and transform healthcare delivery models. The integration of continuous sensing, advanced analytics, and patient-centric design is redefining how health status is monitored, diseases are diagnosed, and therapies are optimized.

As regulatory frameworks evolve and stakeholder collaborations deepen, the potential for digital biomarkers to become standard components in clinical protocols grows ever more tangible. Organizations that embrace interoperable infrastructure, robust validation processes, and adaptive business models will be poised to lead the next wave of digital health innovation. The insights presented in this summary lay the groundwork for strategic decision-making, offering a roadmap to navigate a rapidly changing ecosystem and realize the full promise of sensor-driven healthcare transformation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Digital Biomarkers Market, by Component

  • 8.1. Hardware
    • 8.1.1. Implantables
    • 8.1.2. Sensors
    • 8.1.3. Wearables
      • 8.1.3.1. Fitness Bands
      • 8.1.3.2. Smartwatches
  • 8.2. Software

9. Digital Biomarkers Market, by Biomarker Type

  • 9.1. Active
  • 9.2. Passive

10. Digital Biomarkers Market, by Functionality

  • 10.1. Continuous
  • 10.2. Event-Driven
  • 10.3. Periodic

11. Digital Biomarkers Market, by Therapeutic Area

  • 11.1. Cardiology
    • 11.1.1. Arrhythmia
    • 11.1.2. Heart Failure
  • 11.2. Endocrinology
    • 11.2.1. Diabetes Mellitus
    • 11.2.2. Thyroid Disorders
  • 11.3. Neurology
    • 11.3.1. Alzheimer's Disease
    • 11.3.2. Parkinson's Disease
  • 11.4. Oncology
    • 11.4.1. Breast Cancer
    • 11.4.2. Prostate Cancer
  • 11.5. Pulmonology

12. Digital Biomarkers Market, by Application

  • 12.1. Disease Diagnostics
  • 12.2. Drug Development
  • 12.3. Patient Monitoring

13. Digital Biomarkers Market, by End User

  • 13.1. Academic & Research Institutes
  • 13.2. Biotechnology Firms
  • 13.3. Hospitals & Clinics
  • 13.4. Pharmaceutical Companies

14. Digital Biomarkers Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Digital Biomarkers Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Digital Biomarkers Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Digital Biomarkers Market

18. China Digital Biomarkers Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. ActiGraph, LLC
  • 19.6. Adherium Limited
  • 19.7. Altoida, Inc.
  • 19.8. Amgen Inc.
  • 19.9. Aural Analytics, Inc. by Linus Health, Inc.
  • 19.10. Biofourmis Pte. Ltd.
  • 19.11. Biogen Inc.
  • 19.12. Brainomix Limited
  • 19.13. Chugai Pharmaceutical Co., Ltd.
  • 19.14. Eli Lilly and Company
  • 19.15. Empatica Inc.
  • 19.16. F. Hoffmann-La Roche Ltd.
  • 19.17. Feel Therapeutics Inc.
  • 19.18. GERO PTE. LTD.
  • 19.19. Huma Therapeutics Limited
  • 19.20. ICON PLC
  • 19.21. IXICO PLC
  • 19.22. Koneksa Health Inc.
  • 19.23. Medable Inc.
  • 19.24. Owkin, Inc.
  • 19.25. Sonde Health, Inc
  • 19.26. Teva Pharmaceutical Industries Ltd.
  • 19.27. Verily Life Sciences, LLC
  • 19.28. VivoSense, Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIGITAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DIGITAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA DIGITAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY IMPLANTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY IMPLANTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY IMPLANTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SENSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SENSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SENSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FITNESS BANDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FITNESS BANDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FITNESS BANDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SMARTWATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SMARTWATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SMARTWATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ACTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ACTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ACTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PASSIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PASSIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PASSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CONTINUOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CONTINUOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CONTINUOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY EVENT-DRIVEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY EVENT-DRIVEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY EVENT-DRIVEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PERIODIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PERIODIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PERIODIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ARRHYTHMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ARRHYTHMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DIABETES MELLITUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DIABETES MELLITUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DIABETES MELLITUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THYROID DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THYROID DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PULMONOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PULMONOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PULMONOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PATIENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PATIENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. GCC DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 231. GCC DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 232. GCC DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 233. GCC DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. GCC DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 235. GCC DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 236. GCC DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. GCC DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. GCC DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. GCC DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. GCC DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. G7 DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 269. G7 DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 270. G7 DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 271. G7 DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 272. G7 DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. G7 DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 274. G7 DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 275. G7 DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. G7 DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. G7 DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. G7 DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. G7 DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. G7 DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. NATO DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. NATO DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 283. NATO DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 284. NATO DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 285. NATO DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. NATO DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 287. NATO DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 288. NATO DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 289. NATO DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. NATO DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. NATO DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. NATO DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. NATO DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA DIGITAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)